Novozymes is the world leader in bioinnovation, producing a wide range of industrial enzymes, microorganisms, and biopharmaceutical ingredients.
April 24 2014
Strong Q1 performance; full-year profit outlook increased
February 26 2014
Today Novozymes A/S held its Annual Shareholders’ Meeting.
February 10 2014
On February 17, 2014, Novozymes will initiate a stock buyback program as announced in Company announcement No. 29 of December 10, 2013.
Stærkt 1. kvartal; opjusterede forventninger til årets resultat
I dag har Novozymes A/S afholdt ordinær generalforsamling.
Den 17. februar 2014 vil Novozymes påbegynde et aktietilbagekøbsprogram, således som offentliggjort i selskabsmeddelelse nr. 29 af 10. december 2013.
Sales of enzymes to the bioenergy industry increase by 34% as customers embrace new technology.
$36 million North Carolina facility to create 100 new science jobs
April 23 2014
The European Commission has granted marketing approval to GlaxoSmithKline’s new type 2 diabetes medicine, Eperzan® (albiglutide). The drug uses albumin technology from Novozymes to extend the drug’s presence in the patient’s body.
March 31 2014
| Copyright © 2014 Novozymes. All Rights Reserved.